IgM nephropathy - Successful treatment with rituximab. Saudi J Kidney Dis Transpl 2019;30(1):235-238
Date
02/26/2019Pubmed ID
30804288DOI
10.4103/1319-2442.252917Scopus ID
2-s2.0-85062165806 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
Immunoglobulin M nephropathy (IgMN) is a primary glomerulonephritis which is characterized by variable degrees of morphological features ranging from minimal glomerular involvement to segmental or global sclerosis. No specific treatment is known to date for this disease because of uncertainties in etiopathogenesis. The mainstay treatment for this disease has been corticosteroids, which has varying degrees of resistance ranging from 0% to 50%. We present the case of a 59-year-old Caucasian male who was referred to the outpatient nephrology clinic for the evaluation of proteinuria and was diagnosed with IgMN. We successfully treated the patient with rituximab with resolution of his proteinuria.
Author List
Ahmed FA, El-Meanawy AAuthor
Ashraf El-Meanawy MD, PhD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
GlomerulonephritisHumans
Immunoglobulin M
Immunologic Factors
Male
Middle Aged
Proteinuria
Rituximab
